Wockhardt Ltd reported a sharp widening of its consolidated net loss to INR 108 crore for the June quarter of FY26, compared to INR 16 crore in the same period last year.

The loss was mainly driven by an INR 97 crore goodwill impairment following the company’s permanent exit from the US generics market and the voluntary liquidation of its Delaware-based subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC.

Revenue for the quarter remained largely flat at INR 738 crore, compared to INR 739 crore a year ago, while total expenses fell marginally to INR 770 crore from INR 775 crore. The company said the move is part of its strategic shift towards drug discovery and biologics, with a focus on novel antibiotics and insulin portfolios.

Wockhardt noted that the exit from the US generics market will help streamline operations and reallocate resources towards high-growth markets, including India, the UK, and emerging economies. The company remains optimistic about its long-term prospects, citing a robust pipeline of innovative products under development and ongoing efforts to strengthen its presence in speciality segments such as critical care and chronic therapies.